Reference
1. Baena-Cagnani CE, Berger WE, DuBuske LM, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.International archives of allergy and immunology.2003;130(4):307-313.
2. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax.2003;58(3):211-216.
3. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Archives of internal medicine. 1998;158(11):1213-1220.
4. Aagaard L, Hansen EH. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011. Int J Clin Pharm. 2014;36(6):1222-1229.
5. Aldea Perona A, Garcia-Saiz M, Sanz Alvarez E. Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase((R)). Drug safety. 2016;39(1):69-78.
6. Bygdell M, Brunlof G, Wallerstedt SM, Kindblom JM. Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiology and drug safety.2012;21(1):79-86.
7. Callero-Viera A, Infante S, Fuentes-Aparicio V, Zapatero L, Alonso-Lebrero E. Neuropsychiatric reactions to montelukast.Journal of investigational allergology & clinical immunology.2012;22(6):452-453.
8. Cereza G, Garcia Dolade N, Laporte JR. Nightmares induced by montelukast in children and adults. The European respiratory journal. 2012;40(6):1574-1575.
9. Ibarra-Barrueta O, Palacios-Zabalza I, Mora-Atorrasagasti O, Mayo-Suarez J. Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events. The Annals of pharmacotherapy.2014;48(1):145-148.
10. Kocyigit A, Gulcan Oksuz B, Yarar F, Uzun F, Igde M, Islek I. Hallucination development with montelukast in a child with asthma: case presentation. Iranian journal of allergy, asthma, and immunology.2013;12(4):397-399.
11. Lafay-Chebassier C, Chavant F, Favreliere S, Pizzoglio V, Perault-Pochat MC. Drug-induced Depression: a Case/Non Case Study in the French Pharmacovigilance Database. Therapie. 2015;70(5):425-432.
12. Mann PBLWGPSFSSRD. Pharmacosurveillance and safety of the leukotriene receptor antagonist (LTRA), montelukast. Clin Exp Allergy Rev. 2001:300-304.
13. Marchand MS, Jonville-Bera AP, Autret-Leca E. [Psychiatric disorders associated with montelukast: data from the National Pharmacovigilance Database]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 2013;20(3):269-273.
14. Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiology and drug safety. 2009;18(9):858-864.
15. US Food and Drug Administration:FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair). https://wwwfdagov/drugs.2020;accessed 1 March 2020.
16. US Food and Drug Administration:Early Communication about an ongoing safety review of montelukast (Singulair).http://wwwfdagov/Drugs 2008;accessed 1 March 2020.
17. US Food and Drug Administration:Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR).http://wwwfdagov/Drugs 2009;accessed 1 March 2020.
18. Narang R, Narang S, Narang D, Udeani G. Contemporary use of montelukast and its association with depression in asthma and allergic rhinitis patients. Chest. 2014;146(4):13A.
19. Jadad AR. Randomised Controlled Trials. 1998;London: BMJ Publishing Group.
20. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions,v.5.1. Cochrane Collaboration Web site. 2011.
21. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. Jama. 1998;279(15):1181-1186.
22. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. The New England journal of medicine. 1998;339(3):147-152.
23. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. The European respiratory journal. 1998;11(6):1232-1239.
24. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Annals of internal medicine. 1999;130(6):487-495.
25. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. The Journal of allergy and clinical immunology. 2000;105(5):917-922.
26. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2002;88(6):592-600.
27. Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. The European respiratory journal.2003;21(1):123-128.
28. Yildirim Z, Ozlu T, Bulbul Y, Bayram H. Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma.Respirology (Carlton, Vic). 2004;9(2):243-248.
29. Shah AR, Sharples LD, Solanki RN, Shah KV. Double-blind, randomised, controlled trial assessing controller medications in asthma.Respiration; international review of thoracic diseases.2006;73(4):449-456.
30. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. American journal of respiratory and critical care medicine. 2007;175(3):235-242.
31. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatric pulmonology. 2009;44(6):568-579.
32. Prenner BM, Lu S, Danzig MR. Safety of fixed-dose loratadine/montelukast in subjects with allergic rhinitis. Allergy and asthma proceedings. 2010;31(6):493-498.
33. Bernstein JA. Allergic and mixed rhinitis: Epidemiology and natural history. Allergy and asthma proceedings. 2010;31(5):365-369.
34. Martinez FD, Vercelli D. Asthma. Lancet (London, England).2013;382(9901):1360-1372.
35. Dockhorn RJ, Bergner A, Connell JT, et al. Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Annals of allergy. 1987;58(6):407-411.
36. Timonen M, Jokelainen J, Silvennoinen-Kassinen S, et al. Association between skin test diagnosed atopy and professionally diagnosed depression: a Northern Finland 1966 Birth Cohort study. Biological psychiatry. 2002;52(4):349-355.
37. Kovacs M, Stauder A, Szedmak S. Severity of allergic complaints: the importance of depressed mood. Journal of psychosomatic research.2003;54(6):549-557.
38. Eyre H, Baune BT. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology. 2012;37(9):1397-1416.
39. Djuric VJ, Cox G, Overstreet DH, Smith L, Dragomir A, Steiner M. Genetically transmitted cholinergic hyperresponsiveness predisposes to experimental asthma. Brain, behavior, and immunity.1998;12(4):272-284.
40. Overstreet DH, Daws LC, Schiller GD, Orbach J, Janowsky DS. Cholinergic/serotonergic interactions in hypothermia: implications for rat models of depression. Pharmacology, biochemistry, and behavior. 1998;59(4):777-785.